The U.S. Food and Drug Administration (FDA) has announced a new initiative aimed at accelerating the repurposing of already approved medicines to treat diseases with significant unmet medical needs, including rare disorders, neurodegenerative diseases, metabolic conditions, and substance use disorders.

OneSource Specialty Pharma Limited has announced a strong recovery in its fourth quarter performance for FY26, driven by growth across all major business segments and the commercial launch of semaglutide products in India. The company also reaffirmed its FY28 guidance of achieving nearly USD 400 million in organic revenue with around 40% EBITDA margin.

-- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.

Centurion University’s School of Pharmacy and Life Sciences (SoPLS) is an institution established on 2016 dedicated to touch human lives in healthcare and happiness to ensure holistic societal development through skill based education, research, drug development and community welfare services, SoPLS committed to undertake the task of meeting professional and social needs like identification, cure, mitigation of disease and innovative drug design. It focuses in fulfiling student’s career in pharmaceutical sector, research and entrepreneurship.

Applications are invited for the position of Project Research Scientist-II (Non-Medical) in the ICMR funded project titled “A Randomized Trial of Enhanced Immunosuppression versus antifibrotic therapy and drug response prediction in progressive pulmonary fibrosis (RUNNER trial). (Project Code 1-1872) on temporary basis.

Post : Project Research Scientist-II I (Non- Medical)